In a company release, Horizon Therapeutics announced results from a phase 2/3 trial demonstrating that its B-cell-depleting agent Uplizna reduced the severity of attacks in people with neuromyelitis optica spectrum disorder.
According to the release, data from the 28-week, randomized-controlled N-MOmentum trial showed that 89% of 161 patients in the Uplizna (inebilizumab-cdon, Horizon Therapeutics) treatment group remained attack-free compared with 58% of 52 patients in the placebo group.
“NMOSD attacks can be incredibly detrimental to the well-being of patients,” Jeffrey Bennett,